Redondo, S, Esquirol, A, Novelli, S, Caballero, AC, Garrido, A, Onate, G, Lopez, J, Moreno, C, Saavedra, SD, Granell, M, Briones, J, Sierra, J, Martino, R, Garcia-Cadenas, I. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. Transplantation And Cellular Therapy. 2022; 28(1)DOI:10.1016/j.jtct.2021.10.015. PMID:34757054. IF:3.200(Q2/5D).

Arguello-Tomas M., Albiol N., Jara P., Sierra J., Mora A., Moreno C.. CLL-477 Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01349-0. PMID:36163896. IF:(Q/D).

Santos M.F., Almorox R.B., Solan L., Lopez O., Gallardo A., Garcia-Avila S., Esquirol A., Ferra C., Martin A., Garcia A., Perez E., Colorado M., Cortes M., Cabrero M., Gayoso J., Yañez L., Pascual M.J., Heras I.D.L., Diez J.L., Caballero M.D., Kwon M., Corral L.L.. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC). Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01659-7. PMID:36164212. IF:(Q/D).

Munir T., Moreno C., Owen C., Follows G., Benjamini O., Janssens A., Levin M.-D., Osterborg A., Robak T., Simkovic M., Stevens D., Voloshin S., Vorobyev V., Yagci M., Ysebaert L., Qi Q., Steele A., Schuier N., Baeten K., Caces D.B., Niemann C., Kater A.. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01322-2. PMID:36163867. IF:(Q/D).